Screener
Summit Therapeutics SMMT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.01 par value: 1,000,000,000 shares authorized; 776,017,474 and 775,371,200 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 7,760 | 7,754 |
| Additional paid-in capital | 3,024,387 | 2,947,805 |
| Accumulated other comprehensive loss | (2,632) | (2,540) |
| Accumulated deficit | (2,483,583) | (2,294,159) |
| Total stockholders' equity | 545,932 | 658,860 |
| Total liabilities and stockholders' equity | $647,856 | $751,182 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's total equity?
- Summit Therapeutics (SMMT) reported total equity of $545.93M in Q1 2026.
- How has Summit Therapeutics's total equity changed year-over-year?
- Summit Therapeutics's total equity increased by 58.5% year-over-year, from $344.33M to $545.93M.
- What is the long-term trend for Summit Therapeutics's total equity?
- Over 5 years (2020 to 2025), Summit Therapeutics's total equity has grown at a 52.7% compound annual growth rate (CAGR), from $79.45M to $658.86M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Summit Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude